Side effects to note of Nabumeton 750 mg

Nabumeton 750 mg is used in the treatment of osteoarthritis and rheumatoid arthritis. As a non-steroidal anti-inflammatory drug, the use of Nabumeton 750 mg requires a lot of information, especially the risk of gastrointestinal bleeding.

Nabumeton 750 mg belongs to the group of non-steroidal anti-inflammatory drugs, with the main ingredient being Nabumetone. Nabumetone exerts anti-inflammatory effects by inhibiting prostaglandin synthesis.
Nabumeton 750 mg is formulated as a film-coated tablet and is indicated for the treatment of osteoarthritis, pain relief and anti-inflammatory in rheumatoid arthritis. In addition to the 750mg tablet form, the drug also has a strength of 500mg.

Nabumeton 750 mg is taken orally, 1 tablet whole with water, can be taken with food or after eating.
The usual dose of Nabumeton 750 mg tablets is 1 tablet / time / day, taking the drug at bedtime. In case of severe and prolonged symptoms or sudden onset, the dose can be taken as 2 tablets/day, morning and evening.
Overdose of Nabumeton 750 mg can cause symptoms such as epigastric pain, nausea, vomiting, gastrointestinal bleeding, diarrhea. For Nabumeton 750 mg overdose, so far there is no specific antidote, patients are mainly treated symptomatically.

Taking Nabumeton 750 mg medicine can cause some unwanted side effects with the frequency of occurrence as follows:
Common: Abdominal pain, nausea, vomiting, flatulence, indigestion, constipation, diarrhea , gastritis . Itching, rash, hypertension, edema. Ear disorders, tinnitus. Uncommon: Dry mouth, stomatitis, peptic ulcer, dyspepsia and bleeding Gl, black stools. Headache, dizziness, fatigue, drowsiness, insomnia, anxiety, psychosis, confusion, sensitivity. Nabumeton 750 mg rarely causes facial disturbances, changes in vision. Sweating, urticaria, respiratory disturbances, dyspnea, nosebleeds, weakness. Increased liver enzymes, urinary tract disorders, myopathy. If you see any strange symptoms after taking Nabumeton 750 mg, the patient should immediately notify the doctor or go to a medical facility soon for a health check.

Do not use Nabumeton 750 mg in people with hypersensitivity to the ingredients of the drug; people with a history of hypersensitivity reactions to aspirin, ibuprofen or other non-steroidal anti-inflammatory drugs. People with gastroduodenal disease, recurrent gastric ulcer or perforation, gastrointestinal bleeding, people with liver failure, kidney failure, severe heart failure; Women who are in the last 3 months of pregnancy or are breastfeeding.
Nabumeton 750 mg should also not be used in people with a history of gastrointestinal perforation or bleeding but related to non-steroidal anti-inflammatory drugs. Patients with cerebrovascular accident or cerebral hemorrhage; people with rare hereditary problems such as galactose intolerance, glucose/galactose malabsorption or Lapp lactase deficiency.
People with a history of bronchial asthma related to non-steroidal anti-inflammatory drugs, liver disease, kidney disease, cardiovascular disease, history of gastrointestinal disease should be cautious when using Nabumeton 750 mg.
If the patient is taking different non-steroidal anti-inflammatory drugs concurrently, caution or avoid Nabumeton 750 mg.
Elderly people have a higher risk of side effects when taking non-steroidal anti-inflammatory drugs in general or Nabumeton 750 mg in particular, such as perforation or gastrointestinal bleeding, which can cause death.
People with cardiovascular disease, liver and kidney disease may have kidney failure faster if taking Nabumeton 750 mg in high doses, especially the elderly, taking diuretics, severe renal impairment (with creatinine clearance << 30 ml/min). Therefore, it is necessary to check renal function before and during administration of the drug.
Patients with a history of high blood pressure, congestive heart failure (mild to moderate) due to previous non-steroidal anti-inflammatory drugs should be monitored and prescribed an appropriate dose of Nabumeton 750 mg. Patients with a history of peptic ulcer, perforation, or bleeding in the gastrointestinal tract should receive the lowest possible initial dose of Nabumeton 750 mg because the risk of gastrointestinal ulceration, perforation, or bleeding is higher with higher doses. The drug should be stopped immediately when gastrointestinal bleeding occurs.
Patients with lupus erythematosus or mixed connective tissue disorders have a higher risk of aseptic meningitis when taking Nabumeton 750 mg.
It should be noted, if the patient has any serious skin reactions such as exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, eosinophilia, systemic symptoms are life-threatening. life should immediately stop taking Nabumeton 750 mg.
Women of childbearing age, intending to become pregnant or trying to conceive should not take Nabumeton 750 mg.
If Nabumeton 750 mg is used concurrently with diuretics, ACE inhibitors, angiotensin receptor antagonists, the effect of Nabumeton may be reduced. Especially in the elderly can reduce kidney function, dehydration. Rehydration therapy is required and patients taking these medications should be regularly monitored.
Concomitant administration of Nabumeton 750 mg with potassium-sparing diuretics increases the concentration of potassium in the blood; with cardiac glycosides can worsen heart failure, reduce GFR and increase plasma glycosides, with lithium reduce lithium elimination; with Methotrexate reduces the elimination of methotrexate; with ciclosporin increases the risk of nephrotoxicity.
Concomitant administration of Nabumeton 750 mg with mifepristone may reduce the effect of mifepristone. Therefore, within 8-12 days after taking mifepristone, do not take Nabumeton.
Concomitant use of Nabumeton 750 mg with corticosteroids increases the risk of gastrointestinal ulceration or bleeding; with anticoagulants may increase the anticoagulant effect; with Probenecid reduces the metabolism and elimination of Nabumetone; with quinolone antibiotics may increase the risk of convulsions. Co-administration of Nabumeton 750 mg with alcohol, bisphosphonates, oxpentifylline, sulfinpyrazone, antiplatelet agents and selective serotonin reuptake inhibitors may increase the risk of adverse events and ulceration - gastrointestinal bleeding. With Tacrolimus may increase the risk of causing kidney toxicity; with zidovudine may increase the risk of blood poisoning.
Caution should be taken when administering Nabumeton 750 mg concurrently with other protein-binding drugs, as manifestations of overdose may occur. Patients should be monitored while taking these drugs.
Side effects to watch out for when taking Nabumeton 750 mg are gastrointestinal manifestations and hypersensitivity reactions. Especially the risk of ulceration, perforation or gastrointestinal bleeding can occur when the patient overdose or has a history of or is taking some other drugs.
Hopefully, the above sharing helps you better understand how to use Nabumeton 750 mg as well as the notes to avoid to achieve better results.